Correlation Between In8bio and Cue Biopharma
Can any of the company-specific risk be diversified away by investing in both In8bio and Cue Biopharma at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining In8bio and Cue Biopharma into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between In8bio Inc and Cue Biopharma, you can compare the effects of market volatilities on In8bio and Cue Biopharma and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in In8bio with a short position of Cue Biopharma. Check out your portfolio center. Please also check ongoing floating volatility patterns of In8bio and Cue Biopharma.
Diversification Opportunities for In8bio and Cue Biopharma
-0.2 | Correlation Coefficient |
Good diversification
The 3 months correlation between In8bio and Cue is -0.2. Overlapping area represents the amount of risk that can be diversified away by holding In8bio Inc and Cue Biopharma in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Cue Biopharma and In8bio is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on In8bio Inc are associated (or correlated) with Cue Biopharma. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Cue Biopharma has no effect on the direction of In8bio i.e., In8bio and Cue Biopharma go up and down completely randomly.
Pair Corralation between In8bio and Cue Biopharma
Given the investment horizon of 90 days In8bio Inc is expected to generate 1.78 times more return on investment than Cue Biopharma. However, In8bio is 1.78 times more volatile than Cue Biopharma. It trades about 0.01 of its potential returns per unit of risk. Cue Biopharma is currently generating about -0.01 per unit of risk. If you would invest 238.00 in In8bio Inc on August 27, 2024 and sell it today you would lose (206.00) from holding In8bio Inc or give up 86.55% of portfolio value over 90 days.
| Time Period | 3 Months [change] |
| Direction | Moves Against |
| Strength | Insignificant |
| Accuracy | 100.0% |
| Values | Daily Returns |
In8bio Inc vs. Cue Biopharma
Performance |
| Timeline |
| In8bio Inc |
| Cue Biopharma |
In8bio and Cue Biopharma Volatility Contrast
Predicted Return Density |
| Returns |
Pair Trading with In8bio and Cue Biopharma
The main advantage of trading using opposite In8bio and Cue Biopharma positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if In8bio position performs unexpectedly, Cue Biopharma can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Cue Biopharma will offset losses from the drop in Cue Biopharma's long position.| In8bio vs. Reviva Pharmaceuticals Holdings | In8bio vs. Cue Biopharma | In8bio vs. Lantern Pharma | In8bio vs. Anixa Biosciences |
| Cue Biopharma vs. Coya Therapeutics, Common | Cue Biopharma vs. Lantern Pharma | Cue Biopharma vs. Fennec Pharmaceuticals | Cue Biopharma vs. Eliem Therapeutics |
Check out your portfolio center.Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the CEOs Directory module to screen CEOs from public companies around the world.
Other Complementary Tools
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
| CEOs Directory Screen CEOs from public companies around the world | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities |